Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte is a clinical-stage vaccine company with a strong product pipeline and unique XpressCF technology, making them well-positioned for success in the expanding PCV market. Their VAX-31 vaccine, with superior serotype coverage and favorable results in clinical trials, sets them apart from competitors like Pfizer's Prevnar 20 and Merck's Capvaxive. With a low market cap and potential for continued growth in the PCV market, Vaxcyte is a promising investment opportunity.

Bears say

Vaxcyte is a clinical-stage vaccine company with financial and regulatory risks due to its long development timelines and potential need for additional capital. Recent decisions by the CDC to recommend fewer vaccinations could also affect the adoption of Vaxcyte's vaccines. However, Vaxcyte's differentiated technology and potential for best-in-class pneumococcal vaccine may drive adoption in the market. There are also potential revenue opportunities in the adult population and several novel RSV vaccines in development.

Vaxcyte (PCVX) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Buy based on their latest research and market trends.

According to 4 analysts, Vaxcyte (PCVX) has a Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.